Javerbaum Wurgaft is currently accepting referrals of Zofran cases

Javerbaum Wurgaft is currently accepting referrals of Zofran cases. Zofran is a drug intended to treat nausea from chemotherapy or postoperative symptoms and it was first marketed by GlaxoSmithKline in the United States in 1992.  Zofran has also been prescribed for the treatment of nausea due to pregnancy. This has led to instances of serious birth defects, including cleft palate and cardiac defects. There are also incidences of serotonin syndrome and toxicity to women exposed to Zofran.

We are currently reviewing cases involving birth defects, including cleft palate and cardiac septal defect, when the mother was exposed to Zofran during the first trimester of pregnancy. We are also reviewing cases involving serotonin syndrome and toxicity to adult women. If you have been contacted by any person who may have been injured by these products please Frank Rodriguez (973) 379-4200.